The role of myocardial fibrosis and cardiac adiposity in the pathogenesis of atrial fibrillation
Silkin M.S., Mitrofanova L.B.
Federal State Budgetary Institution “Almazov National Medical Research Centre” of the Ministry of Health of the Russian Federation, 197143, Russian Federation, Saint- Petersburg, 2, Akkuratova str. Department of Pathological Anatomy with a Clinic.
Brief summary
This scientific review systematizes current concepts regarding the role of myocardial fibrosis and epicardial adipose tissue as the fundamental pathomorphological substrates of atrial fibrillation. The literature search and selection were conducted using the PubMed, Scopus, eLIBRARY, and Web of Science electronic databases for the period from 1995 to 2026. The search was performed using keywords and their combinations. The review included original experimental, clinical-morphological, and autopsy studies, as well as international clinical guidelines.
The paper provides a detailed examination of the primary molecular and cellular cascades of fibrogenesis, including the signaling pathways of transforming growth factor-beta, angiotensin II, and hypoxia-inducible factor-1-alpha. The impact of hemodynamic, ischemic, and oxidative stress on the transformation of fibroblasts into myofibroblasts is described. The review analyzes the role of disruptions in the spatial architecture of the extracellular matrix, particularly changes in the ratio between type I collagen and type III collagen, which promote endo-epicardial dissociation and delayed impulse conduction. Furthermore, the study substantiates the significance of epicardial adipose tissue as a paracrine-active organ that secretes profibrotic cytokines and infiltrates the atrial myocardium, creating substrates for micro-re-entry circuits. The contradictions present in the literature concerning unified threshold values for pathological fibrosis and the diagnostic utility of circulating biomarkers are specifically highlighted. The review concludes by emphasizing the high importance of morphological studies for standardizing the criteria for the structural remodeling of the atria.
Key words
atrial fibrillation; atrial fibrosis; pathological anatomy; extracellular matrix; type I and III collagen; epicardial adipose tissue; myofibroblasts; structural remodeling; literature review.
1. Hindricks G., Potpara T., Dagres N., et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021; 42(5): 373-498. https://doi.org/10.1093/eurheartj/ehaa612
2. Wijffels M.C., Kirchhof C.J., Dorland R., Allessie M.A. Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats. Circulation. 1995; 92(7): 1954-1968. https://doi.org/10.1161/01.cir.92.7.1954
3. Kottkamp H. Human atrial fibrillation substrate: towards a specific fibrotic atrial cardiomyopathy. Eur Heart J. 2013; 34(35): 2731-2738. https://doi.org/10.1093/eurheartj/eht194
4. Xintarakou A., Tsoutsina S.A., Sideris G.S., et al. Atrial fibrosis as a dominant factor for the development of atrial fibrillation: facts and gaps. Europace. 2020; 22(3): 342-351. https://doi.org/10.1093/europace/euaa009
5. Kamel H., Okin P.M., Elkind M.S. Atrial fibrillation and mechanisms of stroke: time for a new model. Stroke. 2016; 47(3): 895-900. https://doi.org/10.1161/STROKEAHA.115.012004
6. Goette A., Corradi D., Dobrev D., et al. Atrial cardiomyopathy revisited - evolution of a concept: a clinical consensus statement of the European Heart Rhythm Association (EHRA) of the ESC, the Heart Rhythm Society (HRS), the Asian Pacific Heart Rhythm Society (APHRS), and the Latin American Heart Rhythm Society (LAHRS). Europace. 2024; 26(9): euae204. https://doi.org/10.1093/europace/euae204
7. Sygitowicz G., Maciejak-Jastrzębska A., Sitkiewicz D. A review of the molecular mechanisms underlying cardiac fibrosis and atrial fibrillation. J Clin Med. 2021; 10(19): 4430. https://doi.org/10.3390/jcm10194430
8. Maruyama K., Imanaka-Yoshida K. The pathogenesis of cardiac fibrosis: a review of recent progress. Int J Mol Sci. 2022; 23(5): 2617. https://doi.org/10.3390/ijms23052617
9. Chang Y., Zou Q. Mitochondrial calcium homeostasis and atrial fibrillation: Mechanisms and therapeutic strategies review. Curr Probl Cardiol. 2025; 50(3): 102988. https://doi.org/10.1016/j.cpcardiol.2025.102988
10. Pfenniger A., Yoo S., Arora R. Oxidative stress and atrial fibrillation. J Mol Cell Cardiol. 2024; 196: 141-151. https://doi.org/10.1016/j.yjmcc.2024.09.011
11. Mondragon R.R., et al. Mitochondrial NOX4 drives atrial fibrillation via redox-dependent structural remodeling and fibrosis. Free Radic Biol Med. 2026; 242: 391-403. https://doi.org/10.1016/j.freeradbiomed.2025.10.303
12. Ma J., Chen Q., Ma S. Left atrial fibrosis in atrial fibrillation: mechanisms, clinical evaluation and management. J Cell Mol Med. 2021; 25(6): 2764-2775. https://doi.org/10.1111/jcmm.16350
13. Liu W., et al. Cardiac fibrosis: from mechanisms and models to medicines. Trends Pharmacol Sci. 2025; 46(1): 15-28. https://doi.org/10.1016/j.tips.2025.07.016
14. López B., González A., Ravassa S., et al. Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches. Nat Rev Cardiol. 2021; 18(7): 479-498. https://doi.org/10.1038/s41569-020-00504-1
15. Neuilly O., Le N.A.L., Khairy P., Hiram R. Consequences of Right Heart Disease for Cardiac Electrophysiology and Arrhythmias: Cellular and Structural Mechanisms. CJC Open. 2025; 7(9): 1170-1189. https://doi.org/10.1016/j.cjco.2025.06.013
16. Loncaric F., Forado-Benatar I., Mimbrero G. M. et al. Left atrial adaptation to different overloads: is atrial enlargement always related to atrial dysfunction? Int J Cardiol. 2026; 134675. https://doi.org/10.1016/j.ijcard.2026.134675
17. Moccia F., Faris P., Negri S. et al. Ca2+ signaling in cardiac fibroblasts: an emerging signaling pathway driving fibrotic remodeling in cardiac disorders. Biomedicines. 2025; 13(3): 734. https://doi.org/10.3390/biomedicines13030734
19. Kumar S., Sharma A., Verma R. et al. TRPC3 and TRPC6 as molecular mediators of resistant hypertension and cardiac fibrosis: a new therapeutic frontier. Arterial Hypertens. 2025; 29: 123-132. https://doi.org/10.5603/ah.108127
20. Maesen B., Verheule S., Zeemering S. et al. Endomysial fibrosis, rather than overall connective tissue content, is the main determinant of conduction disturbances in human atrial fibrillation. Europace. 2022; 24(6): 1015-1024. https://doi.org/10.1093/europace/euac026
21. Faria D., Scarsini R., Pesarini G. et al. Age-related structural remodelling of the coronary circulation. Catheter Cardiovasc Interv. 2024; 104(5): 968-979. https://doi.org/10.1002/ccd.31223
22. Zhou F., Wang Y., Zhang L. et al. The role of HIF-1α in atrial fibrillation: recent advances and therapeutic potentials. Rev Cardiovasc Med. 2025; 26(2): 26787. https://doi.org/10.31083/RCM26787
23. Meddeb M., Lopez R., Huby T. et al. Myocardial ultrastructure of human heart failure with preserved ejection fraction. Nat Cardiovasc Res. 2024; 3(8): 907-914. https://doi.org/10.1038/s44161-024-00516-x
24. Guttipatti P., Saadallah N., Ji R. et al. Quantitative 3D electron microscopy characterization of mitochondrial structure, mitophagy, and organelle interactions in murine atrial fibrillation. J Struct Biol. 2024; 216(3): 108110. https://doi.org/10.1016/j.jsb.2024.108110
25. Kosiński A., Bobek-Billewicz B., Piwko G. et al. Arterial hypertension and remodelling of the right ventricle. Folia Morphol (Warsz). 2022; 81(2): 336-342. https://doi.org/0.5603/FM.a2021.0038
27. Li G., Dong S., Wang Y. et al. Research progress of myocardial fibrosis and atrial fibrillation. Front Cardiovasc Med. 2022; 9: 889706. https://doi.org/10.3389/fcvm.2022.889706
28. Takada Y., Takigawa M., Kamata T. et al. Intermittent hypoxia by obstructive sleep apnea is significantly associated with electro-anatomical remodeling of the left atrium preceding structural remodeling in patients with atrial fibrillation. IJC Heart Vasc. 2024; 54: 101490. https://doi.org/10.1016/j.ijcha.2024.101490
29. Imanaka-Yoshida K. Tenascin-C in heart diseases - the role of inflammation. Int J Mol Sci. 2021; 22(11): 5828. https://doi.org/10.3390/ijms22115828
30. Zakeri Zafarghandi E., Jacquemet V. Prevalence of endoepicardial asynchrony and breakthrough patterns in a bilayer computational model of heterogeneous endoepicardial dissociation in the left atrium. PLoS One. 2024; 19(11): e0314342. https://doi.org/10.1371/journal.pone.0314342
31. Ali S.Y., Mohsen Y., Sabareesan S. et al. Transmural heterogeneity in 3D fibrosis distribution is associated with endo-epicardial electrical dyssynchrony in persistent atrial fibrillation. J Physiol. 2026. https://doi.org/10.1113/JP291082
32. Kwan E., Ghafoori E., Good W. et al. Diffuse functional and structural abnormalities in fibrosis: Potential structural basis for sustaining atrial fibrillation. Heart Rhythm. 2025; 22(7): 1820-1828. https://doi.org/10.1016/j.hrthm.2024.10.060
33. Sagris M., Theofilis P., Antonopoulos A.S. et al. Atrial Fibrillation: Pathogenesis, Predisposing Factors, and Genetics. Int J Mol Sci. 2021; 23(1): 6. https://doi.org/10.3390/ijms23010006
34. Gharaviri A., Zeemering S., Verheule S. et al. Epicardial fibrosis explains increased endo-epicardial dissociation and epicardial breakthroughs in human atrial fibrillation. Front Physiol. 2020; 11: 68. https://doi.org/10.3389/fphys.2020.00068
35. Voigt N., Li N., Wang Q. et al. Enhanced sarcoplasmic reticulum Ca2+ leak and increased Na+-Ca2+ exchanger function underlie delayed afterdepolarizations in patients with chronic atrial fibrillation. Circulation. 2012; 125(16): 2059-2070. https://doi.org/10.1161/CIRCULATIONAHA.111.067306
36. Pang Z., Ren Y., Yao Z. Interactions between atrial fibrosis and inflammation in atrial fibrillation. Front Cardiovasc Med. 2025; 12: 1578148. https://doi.org/10.3389/fcvm.2025.1578148
37. Kim H.D., Kim M.S., Kim D.H. et al. Left atrial dysfunction, fibrosis and the risk of thromboembolism in patients with paroxysmal and persistent atrial fibrillation. Int J Heart Fail. 2022; 4(1): 42-53. https://doi.org/10.36628/ijhf.2021.0043
38. Vinciguerra M., Dobrev D., Nattel S. Atrial fibrillation: pathophysiology, genetic and epigenetic mechanisms. Lancet Reg Health Eur. 2024; 37: 100870. https://doi.org/10.1016/j.lanepe.2023.100785
39. Zhang Y., Chen Y., Guo J. et al. From Paroxysmal to Persistent Atrial Fibrillation: Progressive Fibrosis of the Left Atrial Posterior Wall. JACC Cardiovasc Imaging. 2025; 18(10): 1131-1144. https://doi.org/10.1016/j.jcmg.2025.03.013
40. Hopman L.H.G.A., Bhagirath P., Mulder J.M. et al. Extent of Left Atrial Fibrosis Correlates with Descending Aorta Proximity at 3D Late Gadolinium Enhancement Cardiac MRI in Patients with Atrial Fibrillation. Radiol Cardiothorac Imaging. 2022; 4(3): e210192. https://doi.org/10.1148/ryct.210192
41. Yamaguchi T., Nakashima K. Atrial cardiomyopathy and atrial fibrillation: insight from histopathological analysis of atrial biopsies. Korean Circ J. 2025; 56(6): 439-465. https://doi.org/10.4070/kcj.2025.0421
42. Takahashi Y., Yamaguchi T., Otsubo T. et al. Histological validation of atrial structural remodelling in patients with atrial fibrillation. Eur Heart J. 2023; 44(35): 3339-3353. https://doi.org/10.1093/eurheartj/ehad396
43. Marrouche N.F., Wilber D., Hindricks G. et al. Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study. JAMA. 2014; 311(5): 498-506. https://doi.org/10.1001/jama.2014.3
44. Marrouche N.F., Wazni O., McGann C. et al. Effect of MRI-Guided Fibrosis Ablation vs Conventional Catheter Ablation on Atrial Arrhythmia Recurrence in Patients With Persistent Atrial Fibrillation: The DECAAF II Randomized Clinical Trial. JAMA. 2022; 327(23): 2296-2305. https://doi.org/10.1001/jama.2022.8831
45. Jalife J., Kaur K. Atrial remodeling, fibrosis, and atrial fibrillation. Trends Cardiovasc Med. 2015; 25(6): 475-484. https://doi.org/10.1016/j.tcm.2014.12.015
46. Nawaz A., Sohpal A., Mitra R. et al. The Link Between Atrial Fibrosis and Postoperative Atrial Fibrillation After Cardiac Surgery: A Systematic Review. Trends Cardiovasc Med. 2026. https://doi.org/10.1016/j.tcm.2026.04.002
47. Mariscalco G., Engström K.G., Ferrarese S. et al. Relationship between atrial histopathology and atrial fibrillation after coronary bypass surgery. J Thorac Cardiovasc Surg. 2006; 131(6): 1364-1372. https://doi.org/10.1016/j.jtcvs.2006.01.040
48. Corradi D., Saffitz J.E., Novelli D. et al. Prospective evaluation of clinico-pathological predictors of postoperative atrial fibrillation: an ancillary study from the OPERA trial. Circ Arrhythm Electrophysiol. 2020; 13(8): e008382. https://doi.org/10.1161/CIRCEP.120.008382
49. Wittig C., Szulcek R. Extracellular Matrix Protein Ratios in the Human Heart and Vessels: How to Distinguish Pathological From Physiological Changes? Front Physiol. 2021; 12: 708656 https://doi.org/10.3389/fphys.2021.708656
50. Liu J., Liu X., Luo Y. et al. Sphingolipids: drivers of cardiac fibrosis and atrial fibrillation. J Mol Med (Berl). 2024; 102(2): 149-165. https://doi.org/10.1007/s00109-023-02391-8
51. del Monte-Nieto G., Fischer J.W., Gorski D.J. et al. Basic biology of extracellular matrix in the cardiovascular system, part 1/4: JACC focus seminar. J Am Coll Cardiol. 2020; 75(17): 2169-2188. https://doi.org/10.1016/j.jacc.2020.03.024
52. Vanlerberghe R., Colige A., Malfait A.M. et al. ADAMTS2: More than a procollagen N-proteinase. Genes Dis. 2025; 12(6): 101686. https://doi.org/10.1016/j.gendis.2025.101686
53. Hsiao Y.T., Yoshida Y., Tsuchimochi H. et al. PCPE-1 promotes cardiac fibrosis with aging and obesity. JCI Insight. 2026; 11(13): e194206. https://doi.org/10.1172/jci.insight.195508
54. Kalyanasundaram A., Li N., Gardner M.L. et al. Fibroblast-specific proteotranscriptomes reveal distinct fibrotic signatures of human sinoatrial node in nonfailing and failing hearts. Circulation. 2021; 144(2): 126-143. https://doi.org/10.1161/CIRCULATIONAHA.120.051583
55. Depes D., Mennander A., Paavonen T. et al. Detailed study of collagen, vasculature, and innervation in the human cardiac conduction system. Cardiovasc Pathol. 2024; 69: 107603. https://doi.org/10.1016/j.carpath.2023.107603
56. Yamaguchi T. Atrial structural remodeling and atrial fibrillation substrate: A histopathological perspective. J Cardiol. 2025; 85(2): 47-55. https://doi.org/10.1016/j.jjcc.2024.05.007
57. Iwamiya S., Ihara K., Nitta G., Sasano T. Atrial fibrillation and underlying structural and electrophysiological heterogeneity. Int J Mol Sci. 2024; 25(18): 10193. https://doi.org/10.3390/ijms251810193
58. Kostin S., Richter M., Ganceva N. et al. Atrial fibrillation in human patients is associated with increased collagen type V and TGFbeta1. Int J Cardiol Heart Vasc. 2024; 50: 101327. https://doi.org/10.1016/j.ijcha.2023.101327
59. Kanniyappan H., Chathurika Rathnayake R.A., Osamor J. et al. The role of collagen and collagen I/III ratio in pathological conditions: insights into molecular mechanisms and therapeutic approaches. Front Bioeng Biotechnol. 2025; 13: 1679625. https://doi.org/10.3389/fbioe.2025.1679625
60. Odeh A., Dungan G.D., Hoppensteadt D. et al. Interrelationship between inflammatory biomarkers and collagen remodeling proteins in atrial fibrillation. Clin Appl Thromb Hemost. 2023; 29: 10760296231165055. https://doi.org/10.1177/10760296231165055
61. Liu Z., Liu T., Wu G. Atrial cardiomyopathy: from diagnosis to treatment. Rev Cardiovasc Med. 2025; 26(1): 25124. https://doi.org/10.31083/RCM25124
62. Lu D., Wang K. The relationship between obstructive sleep apnea and atrial remodeling, fibrosis and inflammation. PLoS One. 2025; 20(8): e0328540. https://doi.org/10.1371/journal.pone.0328540
63. Willar B., Tran K.V., Fitzgibbons T.P. Epicardial adipocytes in the pathogenesis of atrial fibrillation: An update on basic and translational studies. Front Endocrinol (Lausanne). 2023; 14: 1154824. https://doi.org/10.3389/fendo.2023.1154824
64. Powell-Wiley T.M., Poirier P., Burke L.E. et al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021; 143(21): e984-e1010. https://doi.org/10.1161/CIR.0000000000000973
65. Banerjee D., Mani A. Obesity’s systemic impact: exploring molecular and physiological links to diabetes, cardiovascular disease, and heart failure. Front Endocrinol (Lausanne). 2025; 16: 1681766. https://doi.org/10.3389/fendo.2025.1681766
66. Ihara K., Sasano T. Role of inflammation in the pathogenesis of atrial fibrillation. Front Physiol. 2022; 13: 862164. https://doi.org/10.3389/fphys.2022.862164
67. Tarasova I. V., Vertkin A. L. Rol epikardialnoi jirovoi tkani v razvitii fibrillyacii predserdii: obzor literatyri. Lechashii vrach. - 2024. - №. 7. - S. 17-22. https://doi.org/10.51793/OS.2024.27.7.002
68. Dobrev D., Heijman J., Hiram R. et al. Inflammatory signalling in atrial cardiomyocytes: a novel unifying principle in atrial fibrillation pathophysiology. Nat Rev Cardiol. 2023; 20(3): 145-167. https://doi.org/10.1038/s41569-022-00759-w
69. Wu L., Jiang Z., Meulendijks E.R. et al. Atrial inflammation and microvascular thrombogenicity are increased in deceased COVID-19 patients. Cardiovasc Pathol. 2023; 64: 107524. https://doi.org/10.1016/j.carpath.2023.107524
70. Takahashi N., Abe I., Kira S., Ishii Y. Role of epicardial adipose tissue in human atrial fibrillation. J Arrhythm. 2023; 39(2): 93-110. https://doi.org/10.1002/joa3.12825
71. Ishii Y., Abe I., Kira S. et al. Detection of fibrotic remodeling of epicardial adipose tissue in patients with atrial fibrillation: imaging approach based on histological observation. Heart Rhythm O2. 2021; 2(4): 311-323. https://doi.org/10.1016/j.hroo.2021.05.006
72. Sha R., Baines O., Hayes A. et al. Impact of obesity on atrial fibrillation pathogenesis and treatment options. J Am Heart Assoc. 2024; 13(1): e032277. https://doi.org/10.1161/JAHA.123.032277
73. Cook L.C., Perry M.D., Hill A.P., Thorpe J. Methods to model epicardial adipose tissue-mediated atrial fibrillation. NPJ Cardiovasc Health. 2025; 2(1): 29. https://doi.org/10.1038/s44325-025-00065-7
74. Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol. 2022; 19(9): 593-606. https://doi.org/10.1038/s41569-022-00679-9
75. Frost L., Hune L.J., Vestergaard P. Overweight and obesity as risk factors for atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. Am J Med. 2005; 118(5): 489-495. https://doi.org/10.1016/j.amjmed.2005.01.031
76. Zhu J., Yang Z., Chen X. et al. A stronger association of epicardial fat volume with non-valvular atrial fibrillation than measures of general obesity in Chinese patients undergoing computed tomography coronary angiography. Diabetes Metab Syndr Obes. 2021; 14: 1223-1232. https://doi.org/10.2147/DMSO.S274047
77. Tarzimanova A.I., Bragina A.E., Ponomareva L.A. et al. The Role of Epicardial Adipose Tissue in the Development of Atrial Fibrillation: A Systematic Review and Meta-Analysis. J Clin Med Res. 2026; 18(2): 75-82. https://doi.org/10.14740/jocmr6465
78. Koskinas K.C., Van Craenenbroeck E.M., Antoniades C. et al. Obesity and cardiovascular disease: an ESC clinical consensus statement. Eur J Prev Cardiol. 2025; 32(3): 184-220. https://doi.org/10.1093/eurjpc/zwae279
79. Thanassoulis G., Massaro J.M., O'Donnell C.J. et al. Pericardial fat is associated with prevalent atrial fibrillation: the Framingham Heart Study. Circ Arrhythm Electrophysiol. 2010; 3(4): 345-350. https://doi.org/10.1161/CIRCEP.109.912055
80. Conte M., Petraglia L., Cabaro S. et al. Epicardial adipose tissue and cardiac arrhythmias: focus on atrial fibrillation. Front Cardiovasc Med. 2022; 9: 932262. https://doi.org/10.3389/fcvm.2022.932262